A 29-year-old cisgender woman recently diagnosed with HIV presents to clinic for follow-up. Her baseline laboratory studies showed a CD4 count of 257 cells/mm³ and an HIV RNA level of 142,690 copies/mL. She is not willing to take an Integrase strand transfer inhibitor due to concern for weight gain. She is asking to receive a single tablet regimen. You discuss possible single-tablet regimen options and are planning to use a regimen with a non-nucleoside reverse transcriptase inhibitor (NNRTI) for the anchor drug.